FreeTheAI

Orexo Oral Semaglutide Matches Reference Tablet in Initial Preclinical Study

NeutralLow impact
ORXSEK 6.10 −1.45%

Orexo AB (OMXSTO:ORX) announced that its lead oral semaglutide tablet achieved bioavailability comparable to a reference tablet in an initial preclinical in vivo study. The test used the drug developer's proprietary AmorphOX platform to deliver the large peptide orally.

The milestone demonstrates that AmorphOX can be applied to oral formulations alongside nasal delivery, expanding potential applications for the technology. Working alongside an industry partner, Orexo plans to refine the formulation to evaluate whether it can surpass existing commercial alternatives.

Moving forward, key milestones include additional formulation optimization, potential human clinical trials, and potential formal development partnerships. Shares of Orexo AB were down 1.45 percent to 6.1 SEK following the announcement.

Key points

  • Orexo AB reported that its oral semaglutide lead tablet matched reference bioavailability in a first preclinical in vivo study.
  • The trial tested the application of Orexo's AmorphOX drug delivery platform for oral peptide delivery.
  • Orexo and an industry partner plan to optimize the formulation to evaluate if performance can top existing alternatives.
  • The company is exploring multiple delivery routes, including oral and intranasal options.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the results of Orexo's oral semaglutide study?

In a first preclinical in vivo study, Orexo's AmorphOX-based oral semaglutide tablet showed bioavailability comparable to a reference tablet.

What is Orexo planning to do next with its oral semaglutide tablet?

Orexo and an industry partner plan to optimize the formulation to determine if it can exceed commercially available alternatives and potentially advance into clinical trials.

How does Orexo deliver oral semaglutide?

Orexo utilizes its proprietary AmorphOX platform, expanding its application from intranasal delivery to oral administration of large peptides.